FDA approves new treatment for multiple myeloma


On Nov. 30, the U.S. Food and Drug Administration (FDA) approved Empliciti (elotuzumab) in combination with two other therapies to treat people with multiple myeloma who have received one to three prior medications. Read more.

No posts to display

LEAVE A REPLY

Please enter your comment!
Please enter your name here